来源：Gangtise投研

　　和誉医药（02256.HK）2024年度业绩电话会：2024年公司取得显著成绩，如全球多中心三期临床实验数据优秀，多个项目在ASCO等会议上展示良好疗效与安全性，如FGFR4抑制剂单药治疗肝癌ORR达44%。公司财务首次实现盈利，净利润约2800万人民币，全年收入5.04亿人民币，年底现金储备19.5959亿人民币。2025年公司将推进多个项目，包括中美IND申报、临床试验及新项目启动。公司致力于first in class和best in class项目，未来将继续加大研发投入，推动项目进展，为股东创造长期价值。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.